OakChart

Impact BioMedical Inc

IBOHealthcare·Biotechnology·USA·Nano·AMEX·Nov 12 • 3:59 PM ET

4.77+0.47 (10.93%)
2026-11-12 23:29 CET
Market cap
$41.21M
Revenue, TTM
0.04 USD m
Net income, TTM
1.61 USD m
Free cash flow, TTM
0.12 USD m
EPS diluted, TTM
0.21
Price / earnings
22.98
Compare

Price

IBO against its 20, 50 and 200-day averages
Terms2050200
Patternshover a marker to name it
RS 04.006.008.00164K328KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IBOclose 4.7720-day 3.9050-day 4.89200-day 6.194.7752w low

54.5% under the 52-week high of 10.48 on 5 Mar 2026. 52-week low 2.43 on 16 Oct 2026. Last 15 sessions, 62.4% high to low

Volume 0.43× normal · the line is the 50-bar volume average

Setup. RS line 0
CANSLIM 1 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%; Average Volume: Over 200K — not on the tape: EPS Growth This Year: High (>25%)
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 1 of 5 — fails: Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — not on the tape: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%)
Quality 4 of 5 — fails: Current Ratio: Over 1
Value 2 of 4 — fails: P/E: Under 15; P/B: Under 2
Income 1 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%)
Small Cap 1 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K

Profile

IBO
52-week range, 29% of the way up
2.4310.48

Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The firm focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological and immune related diseases. It is also involved in developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. The company was founded on October 16, 2018 and is headquartered in Houston, TX.

Employees8
IPOSep 16, 2024
Beta2.85
ATR, 14d0.60
Rel volume0.43
Short float0.31%
Insider own7.36%
Inst own0.28%

Snapshot

6 groups

Valuation

Index-
Market Cap$41.21M
Enterprise Value44.44M
Income1.61M
Sales0.04M
Book / share1.18
Cash / share0.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees8
IPOSep 16, 2024

Ratios

Price / earnings22.98
Forward price / earnings-
Price / earnings / growth-
Price / sales1030.26
Price / book4.03
Price / cash2060.53
Price / free cash flow343.42
Value / cash profit-
Value / sales1111.01
Quick Ratio0.02
Current Ratio0.04
Debt / equity0.00
Long-term debt / equity0.00
Options and shortNo / Yes

Earnings

Earnings / share0.21
Earnings next year-
Earnings next quarter-
Earnings this year-
Earnings next year-
Earnings growth, 5 years-
Past earnings growth15.09% -48.52%
Past sales growth- -
Earnings vs last year100.44%
Sales vs last year52.00%
Earnings vs last quarter95.04%
Sales vs last quarter16.67%
Earnings-
Surprise- -

Ownership

Insiders own7.36%
Insider trades-0.14%
Institutions own0.28%
Institution trades0.20%
Return on assets9.32%
Return on equity371.29%
Return on capital15.95%
Gross Margin-4026.32%
Operating margin-12623.68%
Profit Margin4247.37%
20-day average22.28%
50-day average-2.52%
200-day average-22.92%

Technical

Shares out8.54M
Shares floating7.91M
Short / float0.31%
Short ratio1.46
Short interest0.02M
52-week high10.48 -54.5%
52-week low2.43 +96.3%
Volatility9.99% 20.20%
Average range0.60
Strength index56.95
Market sensitivity2.85
Relative volume0.43
Avg Volume16.92K
Volume7,213

Performance

Perf Week8.41%
Perf Month40.15%
Perf Quarter-17.71%
Perf Half Y-31.28%
Perf YTD-25.15%
Perf Year-27.41%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recommendation-
Target Price-
Prev Close4.30
Price4.77
Change %10.93%

Peers

Mkt cap
TickerCompanyMkt cap
ABVCABVC BioPharma Inc25.99M
NNVCNanoViricides Inc34.45M
EXOZeXoZymes Inc37.13M
IGCIGC Pharma Inc21.53M
QNTMQuantum BioPharma Ltd14.40M
FBIOFortress Biotech Inc66.37M
ANVSAnnovis Bio Inc36.16M
CVMCel-Sci Corp20.93M
BHSTBioHarvest Sciences Inc36.95M
SNOASonoma Pharmaceuticals Inc5.93M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
DSS, INC.10% OwnerSep 24 '26Sale7.061561,101589,518Sep 24 07:37 PM
DSS, INC.10% OwnerSep 22 '26Sale0.55723398589,701Sep 24 07:37 PM
DSS, INC.10% OwnerSep 23 '26Sale6.9527188589,674Sep 24 07:37 PM
DSS INC.StockholderApr 22 '26Proposed Sale0.7231,939,77823,064,209Apr 29 06:08 PM
Macko Todd DChief Financial OfficerMar 27 '26Sale0.5643,40024,369155,122Mar 30 09:06 PM
Macko Todd DChief Financial OfficerMar 25 '26Sale0.601,600961198,122Mar 30 09:06 PM
Grady JasonDirectorMar 23 '26Sale0.6550,00032,505250,182Mar 25 07:55 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.79B
ITOTiShares Core S&P Total U.S. Stock Market ETFAUM: 96.50B

News

latest 14 of 46

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.655-1.43-7.735-4.757-27.105-4.7350.2076
Period202020212022202320242025TTM
EPS, quarterly4.659-29.738-1.326-14.858-1.5230.633-0.268-0.082-0.076
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual000000.0320.04
Period202020212022202320242025TTM
Sales, quarterly0000.0070.0180.0070.0070.0030.021
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.9120.9120.9120.9120.9128.298.544
Period202020212022202320242025MRQ
Shares, quarterly0.9120.9120.9580.9660.9668.298.5448.5448.544
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.040.030.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.571.571.121.121.111.110.00
Gross Profit-1.53-1.54-1.12-1.12-1.11-1.110.00
Selling, General and Administrative Excl. Other3.272.732.282.912.342.070.90
Research and Development0.270.340.281.151.231.080.51
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-4.80-4.27-3.40-4.03-3.45-3.19-0.90
Interest Expense-0.791.060.440.460.30-
Unusual Expense-3.829.3920.290.004.100.000.00
Net Income Before Taxes-0.97-14.45-24.74-4.41-7.88-3.24-0.90
Income Taxes-2.58-2.580.030.00-0.62-1.40-0.08
Consolidated Net Income1.61-11.87-24.77-4.41-7.25-1.85-0.81
Net Income From Continuing Operations1.61-11.84-24.71-4.34-7.05-1.30-0.60
Net Income1.61-11.84-24.71-4.34-7.05-1.30-0.60
EPS (Recurring)-0.12-2.11-11.53-4.76-4.59-1.43-0.66
EPS (Basic, Before Extraordinaries)0.21-4.74-27.11-4.76-7.74-1.43-0.66
EPS (Diluted)0.21-4.74-27.11-4.76-7.74-1.43-0.66
EBITDA-3.66-3.12-2.28-2.91-2.34-2.07-0.90
Non-Operating Income (Expense)0.000.000.010.070.140.240.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense1.450.010.02----
Price To Earnings Ratio20.7120.71-14.86---
Price To Sales Ratio1,259.13497.91-----
Gross Margin-4,026.32-4,803.12-----
Operating Margin-12,623.68-13,343.75-----
Net Margin4,247.37-36,993.75-----
Shares Outstanding8.548.290.910.910.910.910.91
Market Capitalization463.63463.6316.6817.26---

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.020.000.010.010.020.010.000.00
Cost of Goods Sold Incl. D&A0.290.280.280.710.290.300.280.28
Gross Profit-0.27-0.28-0.28-0.70-0.27-0.29-0.28-0.28
Selling, General and Administrative Excl. Other0.380.422.010.460.680.860.730.60
Research and Development0.040.080.050.110.050.070.10-
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-0.65-0.70-2.29-1.16-0.95-1.15-1.01-0.88
Interest Expense0.000.00--0.260.260.270.27
Unusual Expense0.000.000.00-3.820.2712.940.0025.96
Net Income Before Taxes-0.64-0.70-2.282.65-1.48-14.35-1.28-27.10
Income Taxes0.000.000.00-2.580.000.000.000.03
Consolidated Net Income-0.64-0.70-2.285.24-1.48-14.35-1.28-27.13
Net Income From Continuing Operations-0.65-0.70-2.295.25-1.47-14.35-1.27-27.11
Net Income-0.65-0.70-2.295.25-1.47-14.35-1.27-27.11
EPS (Recurring)-0.08-0.08-0.270.31-1.33-5.48-1.33-9.80
EPS (Basic, Before Extraordinaries)-0.08-0.08-0.270.63-1.52-14.86-1.33-29.74
EPS (Diluted)-0.08-0.08-0.270.63-1.52-14.86-1.33-29.74
EBITDA-0.36-0.42-2.00-0.87-0.66-0.86-0.73-0.60
Non-Operating Income (Expense)0.000.000.01-0.010.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.000.001.440.010.000.000.00-
Price To Earnings Ratio20.71-------
Price To Sales Ratio1,259.131,417.081,658.241,651.05324.031,126.63--
Gross Margin-1,280.95-9,400.00-3,971.43-10,014.29-1,505.56-4,171.43--
Operating Margin-3,085.71-23,400.00-32,700.00-16,542.86-5,266.67-16,471.43--
Net Margin-3,071.43-23,300.00-32,671.4374,928.57-8,166.67-204,942.86--
Shares Outstanding8.548.548.548.290.970.970.960.91
Market Capitalization463.6349.6064.6952.838.107.8910.5116.68

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments0.002.000.000.000.050.07
Short Term Receivables0.200.180.330.020.200.00
Inventories0.060.000.000.000.000.00
Other Current Assets0.140.270.000.100.040.04
Total Current Assets0.412.450.330.120.290.11
Net Property, Plant & Equipment0.000.020.290.280.000.00
Total Investments and Advances0.000.000.000.784.820.63
Long-Term Note Receivable0.000.020.000.195.080.00
Intangible Assets16.9917.8144.0145.1346.2447.35
Deferred Tax Assets5.434.42----
Other Assets0.000.000.000.000.000.00
Total Assets22.8424.7144.6346.5056.4248.09
Short Term Debt Incl. Current Port. of LT Debt0.008.8812.079.5312.521.06
Accounts Payable0.350.310.830.540.120.01
Other Current Liabilities0.810.590.230.060.010.00
Total Current Liabilities1.169.7913.1410.1312.641.07
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities6.127.683.233.233.865.25
Other Liabilities0.000.000.000.000.000.00
Total Liabilities7.2817.4716.3713.3716.506.32
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.060.060.000.000.00
Common Equity12.614.2025.1629.5636.6137.91
Total Shareholders Equity12.614.2625.2229.5636.6137.91
Accumulated Minority Interest2.952.983.043.113.313.86
Total Equity15.557.2428.2632.6739.9241.77
Total Liabilities & Stockholders Equity22.8424.7144.6346.0356.4248.09
Book Value Per Share1.524.6127.6032.4340.1641.59
Tangible Book Value Per Share-0.53-14.93-20.68-17.08-10.57-10.36
Full-Time Employees8852--
Price to Book Ratio3.633.970.55---
Return on Assets-54.90-71.27-9.52-13.70-2.49-
Return on Equity-140.36-167.62-15.83-21.31-3.50-
Return on Invested Capital-93.89-580.14-17.19-23.85-3.56-1.58
Quick Ratio0.300.250.030.010.020.10
Current Ratio0.350.250.030.010.020.10

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income1.61-11.87-24.77-4.41-7.25-1.85-0.81
Depreciation1.141.151.121.121.111.110.00
Other Funds (Non Cash)-1.9410.8121.370.004.100.000.00
Funds from Operations-1.78-2.49-2.25-3.29-2.66-2.13-0.90
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital1.890.60-0.610.440.420.10-0.00
Cash from Operating Activities0.12-1.89-2.85-2.85-2.24-2.03-0.90
Capital Expenditures0.000.000.00-0.02-0.280.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.00-0.07-4.18-0.63
Purchase of Investments0.000.000.000.00-0.07-4.18-0.63
Sale Or Maturity of Investments0.000.000.000.000.000.000.00
Other Uses0.000.000.000.00-0.01-5.280.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.01-0.35-9.46-0.63
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock0.000.003.730.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock0.000.003.730.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-0.11-0.111.122.872.5511.461.06
Change in Long Term Debt-0.11-0.111.122.872.5511.461.06
Issuance of Long Term Debt0.180.181.122.872.5511.461.06
Reduction of Long Term Debt-0.29-0.290.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.43
Other Financing Activities Uses0.000.000.000.000.000.000.00
Cash from Financing Activities-0.11-0.114.852.872.5511.461.49
Net Change in Cash0.01-2.002.00-0.00-0.04-0.03-0.04
Free Cash Flow0.12-1.89-2.85-2.87-2.52-2.03-0.90
Preferred Dividends (Cash Flow)-0.00--0.000.000.00
Price to Free Cash Flow412.47------
Deferred Taxes & Investment Tax Credit--2.580.030.00-0.62-1.40-0.08

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments0.020.010.020.000.010.62
Short Term Receivables0.010.200.200.200.210.20
Inventories0.060.060.060.060.480.49
Other Current Assets0.010.050.100.140.210.17
Total Current Assets0.100.320.380.410.921.48
Net Property, Plant & Equipment0.000.000.000.000.010.01
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets16.1416.4316.7116.9917.2817.57
Deferred Tax Assets---5.43--
Other Assets0.000.000.000.000.000.00
Total Assets16.4316.7517.0922.8418.2119.06
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.0022.8822.35
Accounts Payable0.450.470.370.350.580.55
Other Current Liabilities1.921.581.310.810.340.27
Total Current Liabilities2.372.041.691.1623.7923.17
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities0.690.690.696.123.273.27
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.062.732.387.2827.0626.44
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.060.06
Common Equity10.1210.7711.4612.61-11.87-10.40
Total Shareholders Equity10.1210.7711.4612.61-11.81-10.34
Accumulated Minority Interest3.253.253.252.952.962.96
Total Equity13.3714.0114.7115.55-8.85-7.38
Total Liabilities & Stockholders Equity16.4316.7517.0922.8418.2119.06
Book Value Per Share1.181.261.341.52-12.29-10.77
Tangible Book Value Per Share-0.70-0.66-0.61-0.53-30.19-28.96
Full-Time Employees---8--
Price to Book Ratio3.634.615.644.19-0.68-0.76
Return on Assets9.324.41-69.25-54.90-136.18-121.80
Return on Equity-371.29-168.00-140.36-452.34-590.45
Return on Invested Capital-6.37-6.49-19.9541.60--
Quick Ratio0.020.130.190.300.020.04
Current Ratio0.040.160.220.350.040.06

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-0.65-0.70-2.285.24-1.47-14.35
Depreciation0.280.280.280.290.290.29
Other Funds (Non Cash)0.000.001.44-3.380.5313.37
Funds from Operations-0.36-0.41-0.56-0.44-0.66-0.70
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.370.890.100.540.040.01
Cash from Operating Activities0.010.47-0.460.10-0.61-0.69
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.00-0.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.00-
Change in Capital Stock0.000.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.00-0.480.48-0.110.000.00
Change in Long Term Debt0.00-0.480.48-0.110.000.00
Issuance of Long Term Debt0.00-0.480.480.180.000.00
Reduction of Long Term Debt0.000.000.00-0.290.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.00-0.480.48-0.110.000.00
Net Change in Cash0.01-0.010.02-0.01-0.61-0.69
Free Cash Flow0.010.47-0.460.10-0.61-0.69
Price to Free Cash Flow412.47-----

Revenue breakdown

Pharmaceutical Preparations2025: 32.00K
United States2025: 32.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.02%0.0M99.9M15.73K
2026-10-150.03%0.0M99.9M12.39K
2026-09-300.03%0.0M99.9M11.07K
2026-09-150.49%0.0M8.5M9.54K
2026-08-310.50%0.0M8.5M4.14K
2026-08-140.51%0.0M8.5M4.26K
2026-07-310.52%0.0M8.5M4.48K
2026-07-150.52%0.0M8.5M5.56K
2026-06-300.52%0.0M8.5M6.93K
2026-06-150.58%0.0M8.5M18.87K
2026-05-290.70%0.1M8.5M341.05K
2026-05-150.73%0.1M8.5M341.14K
2026-04-300.97%0.1M8.3M346.55K
2026-04-151.16%0.1M8.3M351.53K
2026-03-311.83%0.2M8.3M350.20K
2026-03-131.26%0.1M8.3M339.84K
2026-02-271.25%0.0M1.0M8.61K
2026-02-131.16%0.0M1.0M9.13K
2026-01-301.96%0.0M1.0M9.93K
2026-01-152.37%0.0M1.0M10.42K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-11-038-KCurrent report2026-11-02SEC
2026-11-03425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-27DEFM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-098-KCurrent report2026-09-23SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-17425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-09-178-KCurrent report2026-09-16SEC
2026-09-15425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-09-158-KCurrent report2026-09-14SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-29144Filing for proposed sale of securities under Rule 144.SEC
2026-04-22S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-04-06S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-03-304Statement of changes in beneficial ownership of securities2026-03-25SEC
2026-03-254Statement of changes in beneficial ownership of securities2026-03-23SEC
2026-03-1110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-048-KCurrent report2026-02-27SEC
2026-01-064Statement of changes in beneficial ownership of securities2025-05-22SEC
2025-12-30DEF 14CInformation Statement Pursuant to Section 14(c) of the Securities Exchange Act of 19342025-12-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09001.69K3
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030057.84K3
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC0.75%
VANGUARD FIDUCIARY TRUST CO0.55%
BlackRock, Inc.0.24%
NORTHERN TRUST CORP0.22%
GEODE CAPITAL MANAGEMENT, LLC0.09%
CITADEL ADVISORS LLC0.05%
STATE STREET CORP0.05%
Vanguard Global Advisers, LLC0.03%
JANE STREET GROUP, LLC0.02%
TWO SIGMA INVESTMENTS, LP0.02%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.73%
Fidelity Extended Market Index Fund0.51%
Fidelity Total Market Index Fund0.22%
Fidelity Series Total Market Index Fund0.14%
iShares Core S&P Total U.S. Stock Market ETF0.00%

OakChart. IBO. Cached 15 minutes. Terms

Some panels did not load: ratings.